Advitech to present at Biocontact conference in Quebec City


    QUEBEC CITY, Sept. 30 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) a life sciences and technology company
developing evidence based natural health products, today announced that
Dr. Charles Doillon MD, PhD. will be presenting a progress report on the
company's IM technological platform for wound management. The Advitech
presentation is scheduled to begin at 15:00 p.m. local time on Wednesday,
October 1st in the Bellevue room at the Chateau Frontenac Hotel in Quebec
    A fraction from the IM technological platform has demonstrated a dual
bioactive property which could be served either to accelerate wound healing or
to control collagen remodelling. "These latter characteristics are very
important for the proper remodeling in wound repair and their simultaneous
action in one single product would be a unique advantage of the Advitech's
IM-Fraction technological platform" has indicated Dr. Charles Doillon M.D,
PhD. who is piloting this program.
    For the wound healing application, Advitech has a R&D program targeting
the characterization of specific fractions and a toxicology program with
additional in-vitro and in-vivo studies. This significant program should be
completed by year end, or early 2009. As previously stated, the Company
intends to seek a strategic partner to further develop the wound healing


    A recipient of scientific and medical awards, Dr. Doillon is currently a
Full Professor (Dept. Surgery) at Laval University, Quebec City, and
Researcher at the Research Center of the Centre Hospitalier de l'Universite
Laval (CHUL).
    Dr. Doillon has authored and co-authored several scientific publications
and communications in the domain of wound healing, collagen remodelling and
was a pioneer in showing a correlation between collagen fiber distribution and
biomechanics in wound tissues.


    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has drawn up a research program to develop new applications
related to wound healing. This development is derived from both its XP-828L
and IM technological platforms.

    This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF

For further information:

For further information: Renaud Beauchesne, MBA, President and Chief
Executive Officer, Advitech Inc., (418) 686-7498, ext. 228,;
Serge Comeau, Investor's relations, Advitech Inc., (514) 862-4160,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890